Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 12/20 | 0.47 |
| ▸ | NPY1R | P25929 | 8/20 | 0.47 |
| ▸ | NPY2R | P49146 | 7/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.47 |
| ▸ | GHSR | Q92847 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30592734 | 1.00 | NPY4R (0.47) | NPY4RNPY1RNPY2RNPY5RGHSR | |
| SCHEMBL30838802 | 0.94 | NPY4R (0.44) | NPY4RNPY1RNPY2RNPY5RGHSR | |
| SCHEMBL29540760 | 0.92 | GHSR (0.49) | GHSR | |
| SCHEMBL29462006 | 0.92 | GHSR (0.49) | GHSR | |
| SCHEMBL30540722 | 0.89 | NPY4R (0.63) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30059073 | 0.89 | — | — | |
| SCHEMBL6824254 | 0.88 | LNPEP (0.47) | NPY4RNPY1RNPY2R | |
| SCHEMBL6824252 | 0.88 | LNPEP (0.47) | NPY4RNPY1RNPY2R | |
| SCHEMBL29868927 | 0.87 | NPY4R (0.57) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30309227 | 0.87 | NPY4R (0.67) | NPY4RNPY1RNPY2RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11672841-B2 | Methods for treating heart disease in a subject with Friedreich's ataxia by an aromatic-cationic peptide | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11420998-B2 | Aromatic-cationic peptides and methods for using same | STEALTH BIOTHERAPEUTICS INC. (US) | 2022-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11672841-B2 | Methods for treating heart disease in a subject with Friedreich's ataxia by an aromatic-cationic peptide | HAGH, OAT, NLN | NPY4R 886/4885NPY1R 743/4885NPY2R 799/4885 |
| US-11420998-B2 | Aromatic-cationic peptides and methods for using same | ARG2, ARGLU1, ARG1 | NPY4R 824/4885NPY1R 523/4885NPY2R 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.